WHO Unveils First Global Guidelines for Arboviral Disease Management

The World Health Organization (WHO) has issued its first global guidelines aimed at improving the clinical management of arboviral infections, including dengue, Zika virus, chikungunya, and yellow fever. This significant development, announced on July 25, 2025, addresses the rising threat posed by these diseases, which have expanded beyond traditional tropical and subtropical regions due to a confluence of factors such as climate change, urbanization, and increased global travel. With an estimated 5.6 billion individuals now at risk, the guidelines are designed to assist healthcare providers, particularly in resource-limited settings, by providing evidence-based recommendations for diagnosing and managing these infections.
The WHO's guidance emphasizes the increasing incidence of arboviral diseases, which are primarily transmitted by the Aedes aegypti and Aedes albopictus mosquitoes. According to Dr. Maria Neira, Director of Public Health and Environment at WHO, "The simultaneous circulation, frequency, and magnitude of outbreaks of these arboviruses are increasing globally, driven by ecological, economic, and social factors. This necessitates a comprehensive approach to disease management that includes clinician awareness and improved diagnostic capabilities."
Historically, arboviral diseases have been a significant health concern in tropical regions. However, their spread to new areas poses a challenge for healthcare systems worldwide. The guidelines are built upon a systematic review of existing literature and follow previously established protocols by the Pan American Health Organization (PAHO). Dr. Jorge Alvar, a leading expert in arboviral diseases and the principal investigator of the 2022 PAHO handbook, stated, “The expansion of these guidelines to a global context marks a crucial step in combating the public health threats posed by arboviruses.”
One of the critical aspects of the new guidelines is the emphasis on clinical differentiation among arboviral infections. The overlap in early symptoms complicates diagnosis, particularly in regions where multiple arboviruses may circulate simultaneously. As noted in the guidelines, dengue is characterized by thrombocytopenia and a progressive increase in hematocrit, while chikungunya is distinguished by persistent joint pain. Zika infections often present with pruritus, which can further complicate clinical assessment.
The WHO recommends specific management strategies based on disease severity. For patients suspected of having nonsevere arboviral infections, the guidelines advise oral rehydration with small and frequent sips, along with the use of paracetamol or dipyrone for pain and fever management. Notably, corticosteroids are not recommended for nonsevere cases, and the use of nonsteroidal anti-inflammatory drugs should be avoided regardless of the severity of the disease. For severe cases, detailed clinical guidance is provided, including recommendations for intravenous fluid management and monitoring.
The global health community views these guidelines as a vital tool in the fight against arboviral diseases. Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, highlighted the importance of these recommendations: "As arboviral diseases continue to spread, it is imperative that we equip clinicians with the necessary tools and knowledge to effectively manage these infections, especially in regions with limited healthcare resources."
Furthermore, the WHO guidelines underscore the need for laboratory confirmation of arboviral infections, advocating for the integration of diagnostic testing into clinical practice. This is particularly crucial in areas where healthcare infrastructure may be lacking. Dr. Margaret Chan, former Director-General of WHO, remarked, “The introduction of these guidelines represents a proactive approach to a growing health challenge, ensuring that clinicians are prepared to address the complexities of arboviral diseases."
In conclusion, the WHO's global arbovirus guidelines signify a major milestone in public health efforts to manage the increasing incidence of these infections. As climate change and globalization continue to reshape disease epidemiology, these guidelines provide a framework for healthcare systems worldwide to enhance their response to arboviral threats. The future of arboviral disease management will undoubtedly depend on the effective implementation of these recommendations and the continued development of diagnostic and therapeutic strategies.
Advertisement
Tags
Advertisement